BillionToOne, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLLN research report →
Range $120 – $128
Price Chart
About the company
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection.
- CEO
- Oguzhan Atay
- IPO
- 2025
- Employees
- 713
- HQ
- Menlo Park, CA, US
Get TickerSpark's AI analysis on BLLN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.30B
- P/E
- 87.61
- Fwd P/E
- 95.16
- PEG
- 0.05
- P/S
- 9.83
- P/B
- 7.50
- EV/EBITDA
- 65.58
- Div Yield
- 0.00%
- Gross Margin
- 71.41%
- Op Margin
- 10.23%
- Net Margin
- 11.31%
- ROE
- 9.46%
- ROIC
- 6.28%
Latest fiscal year · YoY change
- Revenue
- $305.11M+100.0%
- Gross Profit
- $208.46M+157.6%
- Op Income
- $16.02M
- Net Income
- $7.45M+117.9%
- EPS
- $0.18+104.4%
- OCF Growth
- +159.4%
- FCF Growth
- +133.6%
- 52W High
- $150.44
- 52W Low
- $61.96
- 50D MA
- $106.40
- 200D MA
- $97.90
- Beta
- 0.34
- RSI (14)
- 30
- Avg Volume
- 639.36K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BillionToOne delivered another strong quarter with 47% revenue growth, 71% gross margin, and raised full-year revenue guidance, while setting up a December 15 launch for its Northstar Clear MRD test.· November 4, 2026
- Q3 revenue was $123.0 million, up 47% year over year, with prenatal revenue up 42% to $105.9 million and oncology revenue up 96% to $17.1 million.
- Gross margin held at 70.9% and the company posted $11.0 million of operating income, a 9% operating margin, and $0.32 diluted EPS.
- Test volume rose 25% year over year to about 206,000 tests, helped by a larger sales force, product upgrades, and early EMR integration benefits.
- Management raised 2026 revenue guidance to $460 million-$470 million and said it still expects profitability similar to current levels despite continued investment.
- The company highlighted two clinical publications and said Northstar Clear, its tissue-free MRD test, will launch on December 15 with head-to-head data in colorectal cancer first.
Total revenue in Q3 2026 was $123.0 million, up from $83.5 million in Q3 2025. Prenatal revenue increased 42% to $105.9 million, oncology revenue increased 96% to $17.1 million, and total test volume grew 25% year over year to approximately 206,000 tests. Gross profit was $87.1 million with gross margin of 70.9%, versus 69.9% a year ago. Operating income was $11.0 million, net income available to common shareholders was $17.4 million, and diluted EPS was $0.32. Cash and equivalents ended the quarter at $562 million, cash from operations was $12.5 million, capex was $3.9 million, and free cash flow was $8.6 million. For 2026, revenue guidance was raised to $460 million-$470 million from $450 million-$465 million previously, and management said the company expects profitability similar to current levels; guidance excludes any true-up revenue in Q4.
Oguzhan Atay framed the quarter as proof that all four of the company’s pillars are working: differentiated technology, rapid growth, strong gross margins, and GAAP profitability. He emphasized the value of new clinical evidence, pointing to the Unity Fetal Risk Screen prospective study and the Northstar Response head-to-head study as support for broader adoption and future coverage. His tone was confident and long-term oriented, with Clear’s December launch presented as both a near-term growth event and a strategic step toward early detection.
Ross Taylor focused on the company’s financial execution: 47% year-over-year revenue growth, 70.9% gross margin, 9% operating margin, and 18% adjusted EBITDA margin. He noted that gross profit rose to $87.1 million, operating expenses were $76.1 million, and Q3 generated $12.5 million of operating cash flow and $8.6 million of free cash flow. He also said the balance sheet remains strong with $562 million in cash and equivalents, and that the higher 2026 revenue guide does not include any Q4 true-up revenue.
Analysts pressed on prenatal competition after LabCorp’s FirstGene acquisition, and management said prior consolidations have often created customer disruption that could become an organic growth opportunity. Questions also focused on Northstar Clear: management said it will launch with a low-cost structure, will not be throttled for bottom-line reasons, and will initially use CRC data for head-to-head reimbursement support while broader studies continue across breast, lung, and other cancers. On the Medicare/Coverage front for Response, management said the head-to-head data reduces risk but timing remains uncertain, though they still believe coverage could happen by year-end.
The call showed accelerating oncology momentum, with management saying Northstar Response adoption is growing and Clear could eventually become the biggest revenue contributor among product lines. The company also has substantial cash, strong margins, and raised full-year revenue guidance while maintaining profitability.
Management acknowledged that health-system sales cycles are long, often taking 6 to more than 12 months, and that many of those opportunities are not yet included in guidance. Clear’s near-term revenue contribution is expected to be modest, and reimbursement timing for Response remains uncertain even after the new head-to-head data. The company also flagged that overall COGS per test may rise gradually as oncology becomes a larger share of the mix.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 11.9%
- Shares Outstanding
- 47.77M
- Float Shares
- 5.67M
of shares held by institutions
164 13F filers
Buy/sell ratio 0.17. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Adams Street Partners LLC | 1.71M | 0 |
| Invesco Ltd. | 1.38M | ▲ 547.86K |
| Baillie Gifford & Co | 1.08M | ▲ 180.08K |
| Price T Rowe Associates Inc | 1.05M | ▲ 36.29K |
| Vanguard Capital Management LLC | 1.02M | ▲ 218.83K |
| Vanguard Portfolio Management LLC | 822.29K | ▼ 18.68K |
| Bamco Inc | 743.71K | ▲ 1.61K |
| T. Rowe Price Investment Management, Inc. | 697.91K | ▲ 604.96K |
| Millennium Management LLC | 559.99K | ▲ 134.96K |
| Deep Track Capital, LP | 500.00K | ▲ 500.00K |
| Blackrock, Inc. | 446.08K | ▲ 331.80K |
| D. E. Shaw & Co., Inc. | 428.31K | ▲ 402.32K |
Held by 141 ETFs
Biggest fund positions in BLLN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | KOLLURI KRISHNA KITTU | other | 271,028 |
| Nov 9, 26 | KOLLURI KRISHNA KITTU | other | 129,780 |
| Nov 9, 26 | KOLLURI KRISHNA KITTU | other | 24,222 |
| Nov 9, 26 | KOLLURI KRISHNA KITTU | other | 5,643 |
| Nov 9, 26 | KOLLURI KRISHNA KITTU | other | 23,316 |
| Nov 9, 26 | KOLLURI KRISHNA KITTU | other | 2,302 |
| Nov 9, 26 | KOLLURI KRISHNA KITTU | other | 10,921 |
| Nov 9, 26 | KOLLURI KRISHNA KITTU | other | 5,760 |
| Nov 9, 26 | KOLLURI KRISHNA KITTU | other | 58,290 |
| Nov 9, 26 | KOLLURI KRISHNA KITTU | other | 7,980 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BLLN coverage
Recent articles, reports, and earnings notes.
No research on BLLN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BLLN report →BLLN Investors Have Opportunity to Join BillionToOne, Inc. Fraud Investigation with SBS Law
businesswire.com · Nov 21
BLLN INVESTOR ALERT: Investigation of BillionToOne, Inc. Announced by Holzer & Holzer, LLC
globenewswire.com · Nov 20
BillionToOne (BLLN) Faces Investor Scrutiny Related to Short Report Allegations Driving Shares Lower – HBSS
globenewswire.com · Nov 19
Wolf Popper LLP Announces Investigation on Behalf of BillionToOne, Inc. Investors
globenewswire.com · Nov 19
BillionToOne, Inc. Investor News: If You Have Suffered Losses in BillionToOne, Inc. (NASDAQ: BLLN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
globenewswire.com · Nov 19
Lost Money on BillionToOne, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 6.32% Share Price Drop
businesswire.com · Nov 19
Did You Lose Money on BillionToOne, Inc. Stock? The Law Offices of Howard G.
businesswire.com · Nov 19
Lost Money in BillionToOne, Inc. (NASDAQ: BLLN)? Gibbs Mura is Investigating Potential Securities Law Violations on Behalf of BLLN Investors
gurufocus.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.